[关键词]
[摘要]
[ 摘要 ] 目的 探讨贝伐珠单抗联合紫杉醇、卡铂治疗晚期卵巢癌的临床效果。 方法 选取 2020 年 4 月至 2022 年 2 月德州市第二人民医院肿瘤内科收治的 100 例晚期卵巢癌患者,采用随机数字表法分为对照组和 研究组,每组各 50 例。对照组给予紫杉醇、卡铂治疗,研究组给予贝伐珠单抗联合紫杉醇、卡铂治疗,比较两 组临床效果。 结果 研究组治疗总有效率高于对照组(P < 0.05);治疗后研究组血管内皮生长因子、巨噬细 胞移动抑制因子水平低于对照组(P < 0.05);两组毒副反应总发生率比较,差异无统计学意义(P > 0.05)。 结论 贝伐珠单抗联合紫杉醇、卡铂治疗晚期卵巢癌的临床效果较好,可以提高临床总有效率,降低血管内皮 生长因子、巨噬细胞移动抑制因子水平,不增加毒副反应,值得推广应用。
[Key word]
[Abstract]
[Abstract] Objective To investigate the clinical effect of Bevacizumab combined with Paclitaxel and Carboplatin in the treatment of advanced ovarian cancer Methods A total of 100 patients with advanced ovarian cancer admitted to the Department of Oncology of the Dezhou Second People’s Hospital from April 2020 to February 2022 were selected and divided into control group and study group by random number table method, with 50 cases in each group. The control group was treated with Paclitaxel and Carboplatin, and the study group was treated with Bevacizumab combined with Paclitaxel and Carboplatin. The clinical effect of the two groups was compared. Results The total effective rate of the study group was higher than that of the control group (P < 0.05). The levels of vascular endothelial growth factor and macrophage migration inhibitory factor in the study group were lower than those in the control group after treatment (P < 0.05). There was no significant difference in the total incidence of toxic side effect between the two groups (P > 0.05). Conclusion The clinical effect of Bevacizumab combined with Paclitaxel and Carboplatin in the treatment of advanced ovarian cancer is good, which can improve the total clinical effective rate, reduce the levels of vascular endothelial growth factor and macrophage migration inhibitory factor, and does not increase the toxic side effect, which is worthy of promotion and application.
[中图分类号]
R712
[基金项目]